EC Number   |
Application  |
Reference |
|---|
   3.4.21.46 | drug development |
the enzyme's exosite is a target for design of specific inhibitors for inhibition of the pathway complement activation in advanced dry age-related macular degeneration |
732044 |
| 3.4.21.46 | medicine |
by downregulation of VEGF-D expression in a lung tumor mouse model using Deguielin, a rotenoid of the flavonoid family, tumor-associated lymphangiogenesis and lymphatic metastasis are suppressed |
708769 |
| 3.4.21.46 | medicine |
intravitreal VEGF-D gene transfer causes blood-retina barrier breakdown but not neovessel formation in the rabbit eye. Inflammation-like alterations in the choriocapillaries are observed in the baculoviral VEGF-D-treated eyes, but not in adenoviral VEGF-D-treated eyes at 6 days after gene transfer |
699302 |
| 3.4.21.46 | medicine |
is linked to the control of lymphangiogenesis and lymphatic metastasis. Epigenetic control of histone acetylation represents an important determinant of vegf-D gene expression in cancer cells |
697096 |
| 3.4.21.46 | medicine |
PDGF-D is present in the neointima of the arteriopathy of chronic allograft nephropathy, where it can engage PDGF-Rbeta to promote mesenchymal cell migration, proliferation, and neointima formation. PDGF-D may engage the PDGF-Rbeta to promote interstitial injury in chronic allograft injury |
698194 |
| 3.4.21.46 | medicine |
serum VEGF-D levels are a good biomarker for lymphatic involvement in patients with lympangioleiomyomatosis |
708131 |
| 3.4.21.46 | medicine |
VEGF-D plays an essential role in tumoral lymphangiogenesis and lymphatic spread, VEGF-D expression, and the intratumoral lymphatics may be clinically useful indicators for prognostic evaluation in patients with epithelial ovarian carcinoma |
695580 |
